# RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

> **NCT05869669** · PHASE2 · COMPLETED · sponsor: **EIP Pharma Inc** · enrollment: 159 (actual)

## Conditions studied

- Dementia With Lewy Bodies

## Interventions

- **DRUG:** Neflamapimod
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05869669
- **Lead sponsor:** EIP Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-01
- **Primary completion:** 2025-05-29
- **Final completion:** 2025-06-16
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05869669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05869669, "RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05869669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*